All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.
Bookmark this article
In May 2018, Mary Gleeson from The Royal Marsden NHS Foundation Trust, London and Surrey, UK, and colleagues, published in The Lancet Haematology results from the CHEMO-T (NCT01719835) randomized, open-label, multicenter, phase II trial on the use of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) versus gemcitabine, cisplatin, and methylprednisolone (GEM-P) in previously-untreated patients with peripheral T-cell lymphoma (PTCL).
PTCL is a rare heterogeneous subtype of non-Hodgkin lymphoma with no current consensus on the best first-line chemotherapy regimen for previously-untreated patients. Although, CHOP together with autologous stem cell transplantation is widely used in PTCL, for most patients the outcomes are poor. CHOP in combination with etoposide (CHOEP) has also been investigated for PTCL but with no benefit in patients’ overall survival (OS). Thus, there is an unmet medical need for a superior first-line regimen for PTCL.
Gemcitabine–a nucleoside analog–used as chemotherapy in various carcinomas, is not affected by multidrug resistance 1-P glycoprotein (MDR 1-Pgp) gene which is overexpressed in some PTCL cases and has shown promising activity in the relapsed/refractory PTCL setting. In line with these results and the poor CHOP outcomes in PTCL, this phase II trial sought to comparatively investigate the efficiency of GEM-P and CHOP in naïve PTCL patients. The primary endpoint was the proportion of patients with a CT-based complete response (CR) or unconfirmed complete response (CRu) on trial completion and safety was a secondary endpoint.
The results of this trial indicate that GEM-P is not a more effective regimen than CHOP for previously untreated PTCL patients. Due to the suboptimum CHOP outcomes and the failure of GEM-P in naïve PTCL patients, the authors stated that ‘optimizing therapy for newly-diagnosed patients remains an important unmet medical need’.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox